Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 2
1968 5
1969 6
1970 7
1971 5
1972 8
1973 14
1974 27
1975 26
1976 34
1977 34
1978 37
1979 35
1980 34
1981 31
1982 38
1983 42
1984 37
1985 37
1986 35
1987 41
1988 43
1989 51
1990 49
1991 45
1992 88
1993 82
1994 62
1995 72
1996 102
1997 113
1998 92
1999 86
2000 111
2001 104
2002 126
2003 159
2004 144
2005 167
2006 176
2007 167
2008 180
2009 226
2010 202
2011 229
2012 282
2013 266
2014 263
2015 289
2016 278
2017 264
2018 282
2019 335
2020 326
2021 349
2022 297
2023 275
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

6,295 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Malignant Skin Neoplasm"
Page 1
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Long GV, et al. N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891408 Free article. Clinical Trial.
We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 patients with …
We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with …
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Jóźwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. Reijers ILM, et al. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. Nat Med. 2022. PMID: 35661157 Clinical Trial.
The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization. ...The 24-month …
The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of …
Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Gorry C, et al. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. Cochrane Database Syst Rev. 2023. PMID: 36648215 Free PMC article. Review.
BACKGROUND: Cutaneous melanoma is amongst the most aggressive of all skin cancers. Neoadjuvant treatment is a form of induction therapy, given to shrink a cancerous tumour prior to the main treatment (usually surgery). ...Primary outcomes were overall survival (OS) and adv …
BACKGROUND: Cutaneous melanoma is amongst the most aggressive of all skin cancers. Neoadjuvant treatment is a form of induction thera …
Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
Oglesby A, Algazi AP, Daud AI. Oglesby A, et al. Am J Clin Dermatol. 2019 Dec;20(6):781-796. doi: 10.1007/s40257-019-00452-8. Am J Clin Dermatol. 2019. PMID: 31228012 Review.
Skin cancer, as the most physically accessible malignancy, allows for the greatest variety in treatment innovation. ...Thus, manipulating the tumor microenvironment is a need in skin cancer therapy, which intratumoral delivery can potentially address. ...
Skin cancer, as the most physically accessible malignancy, allows for the greatest variety in treatment innovation. ...Thus, manipula …
Interventions for basal cell carcinoma of the skin.
Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Thomson J, et al. Cochrane Database Syst Rev. 2020 Nov 17;11(11):CD003412. doi: 10.1002/14651858.CD003412.pub3. Cochrane Database Syst Rev. 2020. PMID: 33202063 Free PMC article.
SELECTION CRITERIA: Randomised controlled trials (RCTs) of interventions for BCC in immunocompetent adults with histologically-proven, primary BCC. ...AUTHORS' CONCLUSIONS: Surgical interventions have the lowest recurrence rates, and there may be slightly fewer r …
SELECTION CRITERIA: Randomised controlled trials (RCTs) of interventions for BCC in immunocompetent adults with histologically-proven …
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. Luke JJ, et al. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. Future Oncol. 2020. PMID: 31870188 Free article.
Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in patients with resected stage III melanoma in the Phase III KEYNOTE-054 trial; efficacy in patients with stage II disease has not been …
Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in p …
Adjuvant immunotherapy for melanoma.
Thomas D, Bello DM. Thomas D, et al. J Surg Oncol. 2021 Mar;123(3):789-797. doi: 10.1002/jso.26329. J Surg Oncol. 2021. PMID: 33595889 Review.
High-risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recurrent disease. Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve …
High-risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recur …
Patidegib in Dermatology: A Current Review.
Cosio T, Di Prete M, Di Raimondo C, Garofalo V, Lozzi F, Lanna C, Dika E, Orlandi A, Rapanotti MC, Bianchi L, Campione E. Cosio T, et al. Int J Mol Sci. 2021 Oct 3;22(19):10725. doi: 10.3390/ijms221910725. Int J Mol Sci. 2021. PMID: 34639065 Free PMC article. Review.
BACKGROUND: Basal cell carcinoma is one of the most common types of non-melanoma skin cancers, which can be locally destructive despite low-rate metastasis. ...METHODS: We performed comprehensive research to summarize the use of patidegib in advanced and recurrent a …
BACKGROUND: Basal cell carcinoma is one of the most common types of non-melanoma skin cancers, which can be locally destructive despi …
Treatment of Recurrent Melanoma Following Adjuvant Therapy.
Malissen N, Grob JJ. Malissen N, et al. Am J Clin Dermatol. 2023 May;24(3):333-341. doi: 10.1007/s40257-023-00762-y. Epub 2023 Mar 8. Am J Clin Dermatol. 2023. PMID: 36890427 Review.
Thus, in case of relapse during or just after adjuvant anti-PD-1, immune resistance is probable, an anti-PD-1 monotherapy rechallenge has a low likelihood of clinical benefit, and escalation with a combination of immunotherapies should be given priority. ...Thus, a combina …
Thus, in case of relapse during or just after adjuvant anti-PD-1, immune resistance is probable, an anti-PD-1 monotherapy rechallenge has a …
Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management.
Wuthrick EJ, Chablani P. Wuthrick EJ, et al. Semin Radiat Oncol. 2019 Apr;29(2):166-170. doi: 10.1016/j.semradonc.2018.11.006. Semin Radiat Oncol. 2019. PMID: 30827455 Review.
Despite surgical excision, certain high risk patients with desmoplastic melanoma remain at high risk for local recurrence and retrospective data suggests improvement in local control with adjuvant radiation therapy. Likewise, despite surgical excision and effective systemi …
Despite surgical excision, certain high risk patients with desmoplastic melanoma remain at high risk for local recurrence and retrosp …
6,295 results